Alzheimer's disease

@article{Masters2015AlzheimersD,
  title={Alzheimer's disease},
  author={C. Masters and R. Bateman and K. Blennow and C. Rowe and R. Sperling and J. Cummings},
  journal={Nature Reviews Disease Primers},
  year={2015}
}
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years) and an average clinical duration of 8–10 years. The disease has an estimated prevalence of 10–30% in the population >65 years of age with an incidence of 1–3%. Most patients with Alzheimer's disease (>95%) have the sporadic form, which is characterized by a late onset (80–90 years of age), and is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. A… Expand
Can mouse models mimic sporadic Alzheimer’s disease?
TLDR
The current situation regarding AD mouse models, and the problems to develop a sporadic mouse model of AD are discussed. Expand
Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system.
TLDR
Initial evidence with AD patients shows that a brain-penetrating ACE inhibitor counteracts the process of neurodegeneration and dementia, and centrally acting ACE inhibitors given in addition to the standard therapy, cholinesterase inhibition, can improve cognitive function of AD patients for several months. Expand
Alzheimer’s Disease and Vascular Aging
TLDR
The evidence suggests that vascular pathology is a likely pathogenic contributor to age-related dementia, including Alzheimer’s disease, inextricably linked to disease onset and progression. Expand
Vascular and Metabolic Factors in Alzheimer’s Disease and Related Dementias: Introduction
  • C. Iadecola
  • Medicine
  • Cellular and Molecular Neurobiology
  • 2015
TLDR
Evidence indicates that mixed AD-vascular dementia the most common cause of cognitive impairment in the aged and epidemiological studies have indicated that clinically diagnosed AD and VCI share common risk factors, such as hypertension, obesity, diabetes, etc., suggesting the involvement of common pathogenic factors. Expand
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review
TLDR
Gene clustering into molecular pathways can provide background for identification of novel molecular targets and may support the development of tailored and personalized treatment of AD. Expand
Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis
TLDR
Looking into the multifactorial nature of AD and the overlapping pathology with other forms of dementia, it is important to integrate the core CSF biomarkers with a broader panel of other biomarkers reflecting different aspects of pathology. Expand
Alzheimer's disease: A need for personalized therapeutic approaches
TLDR
Understanding the leading pathological change in each particular AD-like case may be the most important task toward the development of much-needed personalized medicine in AD. Expand
Behavioral and Neuropsychiatric Disorders in Alzheimer's Disease.
TLDR
Inflammation and tau aggregation are observed in preclinical stages, preceding the BNS of patients, which in turn are exhibited earlier than cognitive and functional impairment detected in AD. Expand
Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty
TLDR
Emerging treatments targeting neuroinflammation in AD, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and receptor-interacting serine/threonine protein kinase 1 (RIPK1) that restore calcium dyshomeostasis and microglia physiological function in clearing Aβ plaques, respectively, will be deliberately discussed. Expand
Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease
TLDR
The findings suggest that monocytes regulate the blood levels of Aβ and might be involved in the development of AD and the recovery of the Aβ uptake function by blood monocytes represents a potential therapeutic strategy for AD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 183 REFERENCES
Biology of Aβ Amyloid in Alzheimer's Disease
TLDR
Three of the genes which are now known to be linked to AD, including PS1, beta PP, and apoE, have been established immunohistochemically and biochemically to be components of senile plaques and current data suggest that new therapeutic approaches which may inhibit the aggregation and/or the conformational change of sA beta to A beta fibrils have the greatest likelihood to make a significant impact on controlling amyloid accumulation in AD. Expand
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
TLDR
The strong protective effect of the A673T substitution against Alzheimer’s disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Expand
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
TLDR
It is found that autosomal dominant Alzheimer's disease was associated with a series of pathophysiological changes over decades in CSF biochemical markers of Alzheimer’s disease, brain amyloid deposition, and brain metabolism as well as progressive cognitive impairment. Expand
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
TLDR
The common late-onset form of Alzheimer's disease is characterized by an overall impairment in Aβ clearance, and both Aβ42 and Aβ40 production and clearance rates were impaired in Alzheimer’s disease compared with controls. Expand
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
TLDR
These projections suggest a prolonged preclinical phase of AD in which Aβ deposition reaches the authors' threshold of positivity at 17·0 (95% CI 14·9-19·9) years, hippocampal atrophy at 4·2 (3·6-5·1] years, and memory impairment at 3·3 (2·5-4·5) years before the onset of dementia (clinical dementia rating score 1). Expand
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
TLDR
Despite the short follow-up period, operationalization of the new preclinical AD recommendations confirmed that advancing preclinical stage led to higher proportions of subjects who progressed to MCI or dementia. Expand
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
TLDR
Evidence is observed for quantitative progression of neurofibrillary pathology in advanced cases of AD clearly meeting criteria for stages V and VI and the importance of categorizing classical and primitive plaques with respect to their PHF immunoreactivity has been demonstrated. Expand
Age-specific incidence of Alzheimer's disease in a community population.
TLDR
The incidence of Alzheimer's disease is substantial and is approximately 14 times higher among persons older than 85 years compared with those between 65 and 69 years of age. Expand
Hippocampal sclerosis in advanced age: clinical and pathological features.
TLDR
Age of death and clinical features of hippocampal sclerosis associated with ageing (with or without aberrant TAR DNA protein 43) were distinct from previously published cases of frontotemporal lobar degeneration TARDNA protein 43. Expand
Biochemical markers in persons with preclinical familial Alzheimer disease
TLDR
The finding of elevated F2-isoprostane levels in the CSF of preclinical FAD MCs suggests that oxidative stress occurs downstream to mismetabolism of amyloid precursor protein. Expand
...
1
2
3
4
5
...